Estrella Immunopharma Names Cynthia Pussinen CEO and Board Chair
ESLA has more than doubled off its 52-week low of $0.24 on elevated volume (2.1× avg).
Summary
Estrella Immunopharma appointed Cynthia Pussinen as chief executive officer and chairperson of the board, a combined role that puts one person in charge of both management and the board. Her employment agreement sets a $250,000 base salary rising to $400,000, $450,000 and $525,000 as cumulative funding passes $35M, $55M and $75M, plus a 1,000,000-share option. The change lands at a fragile moment: the company's Q2 10-Q disclosed going concern doubt with only $0.1M of cash against $9.3M in current liabilities, and it has received two Nasdaq delisting notices — one in August for trading below $1.00 for 30 consecutive days and a second in September for failing the $35 million minimum market value requirement. A new CEO inherits a balance sheet that needs financing and a listing that needs fixing, so the market will judge this hire on whether a capital raise or compliance plan follows quickly.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Pussinen's employment agreement sets a $250,000 base salary rising to $400,000, $450,000 and $525,000 as cumulative funding passes $35M, $55M and $75M, plus a 1,000,000-share option.
At the time of this announcement, ESLA was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.8M. The 52-week trading range was $0.24 to $3.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.